Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BenVelPres: Bendamustine + Velcade + prednisone in newly diagnosed multiple myeloma
2011-000293-62Phase 2Active
- Sponsor
- Fundación PETHEMA
- Start
- Nov 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, bendamustine and prednisone in multiple myeloma (MM), sponsored by Fundación PETHEMA. Primary endpoints: Overall response rate to BVP and Complete remission rate with BVP. Started Nov 2011; status: active.
02
Drugs
bortezomibbendamustineprednisone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2011-000293-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000293-62.